secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-10-19T13:22:16+00:00
Accession:  0001193125-26-424755
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

EyePoint's DURAVYU misses Phase 3 LUCIA primary endpoint; 53% workforce cut, wet AMD trials halted
--------------------------------------------------------------------------------

- Phase 3 LUCIA study of DURAVYU in wet AMD did not meet the primary endpoint of non-inferiority, though vision improved and key secondary endpoints were met.
- EyePoint will conclude both pivotal Phase 3 wet AMD trials early, without completing year two, and cut approximately 53% of positions, mostly in Q4 2026, finishing in 1H 2027.
- Restructuring carries about $9M in severance and related charges but is expected to generate roughly $30M in annualized savings.
- Company estimates ~$118M in cash, cash equivalents and short-term investments as of September 30, 2026; figures are preliminary and unaudited.
- Resources now focus on DURAVYU in DME, with Phase 3 COMO and CAPRI (551 patients) topline data expected in Q4 2027; VERONA Phase 2 showed >70% supplement-free at six months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/0001193125-26-424755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-424755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer